Skip to main content
. 2018 Aug 15;7(10):e1490856. doi: 10.1080/2162402X.2018.1490856

Figure 4.

Figure 4.

Ad3-hTERT-E1A-hCD40L, human PBMCs, and human DCs therapy enhanced antitumor effects and survival in mice. Antitumor efficacy (A) and cancer specific survival (B) of humanized mice receiving DC therapy and injections of Ad3-hTERT-CMV-hCD40L or the unarmed control virus Ad3-hTERT-E1A. A549 tumors were implanted subcutaneously in immunodeficient SCID mice lacking B and T-cells. To humanize the white blood cell compartment of the mice, 10 × 106 PBMCs were injected intravenously on day 0 (dashed arrow). Viruses (gray arrows) were injected at 1 × 108 VP and DCs (black arrows), 1X106, were injected intratumorally three times alternatively. Tumor growth was monitored every other day. Ad3-hTERT-CMV-hCD40L and DCs therapy significantly reduced tumor growth as compared with other groups. Tumor growth is expressed as normalized tumor volume based on the values from the first day of virus injection. Data is presented as mean ± SEM. ***, P < 0.001; ****, P < 0.0001. 1A by Two-way ANOVA (Tukey’s post-hoc test) and 1B Kaplan-Meier survival was analyzed bylog-rank test.